MSCs derived from patients with acute myeloid leukemia (AML), but not normal MSCs, highly express p53, suggesting that the p53 pathway is active in the leukemia microenvironment 16, although the extent to which p53 activity in MSCs is relevant to AML progression is poorly understood. This evidence concerns the gene TP53 and acute myeloid leukemia.